瑞康医药：2025年前三季度净利润约1214万元，同比下降63.05%

Group 1 - The core viewpoint of the article highlights that Ruikang Pharmaceutical reported a decline in both revenue and net profit for the third quarter of 2023, indicating potential challenges in its financial performance [1] - The company's revenue for the first three quarters of 2023 was approximately 5.407 billion yuan, a year-on-year decrease of 10.73% [1] - The net profit attributable to shareholders was about 12.14 million yuan, reflecting a significant year-on-year decline of 63.05% [1] - Basic earnings per share were reported at 0.0081 yuan, down 62.84% compared to the previous year [1] Group 2 - As of the report, Ruikang Pharmaceutical's market capitalization stands at 4.4 billion yuan [2]